Korman Abraham M, Reynolds Kelly A, Nabhan Fadi, Konda Bhavana, Shah Manisha H, Kaffenberger Benjamin H
Drs. Korman and Kaffenberger are with the Division of Dermatology in the Department of Internal Medicine at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio.
Ms. Reynolds is with the University of Cincinnati College of Medicine in Cincinnati, Ohio.
J Clin Aesthet Dermatol. 2019 Oct;12(10):35-38. Epub 2019 Oct 1.
Vandetanib is a tyrosine kinase inhibitor approved by the United States Food and Drug Administration for the treatment of metastatic medullary thyroid cancer. It has been linked to a variety of dermatologic reactions, including photosensitivity. We describe the case of a 55-year-old man who developed a severe, painful, erythematous, bullous eruption in sun-exposed areas one month after the initiation of vandetanib. The eruption was initially refractory to treatment with steroids and did not resolve with strict sun avoidance, but finally cleared after a few weeks of oral supplementation with () extract. is an extract derived from a tropical fern, with antioxidant effects that mitigate ultraviolet-induced cutaneous erythema via inflammatory interference and the promotion of other cytotoxic responses. This case illustrates the potential for to be used as a safe and effective photoprotective agent for refractory phototoxic reactions. Further randomized, controlled trials are needed to better understand the mechanism of action and photoprotective properties of in the treatment of tyrosine kinase-induced phototoxicity and other dermatoses.
凡德他尼是一种酪氨酸激酶抑制剂，已被美国食品药品监督管理局批准用于治疗转移性甲状腺髓样癌。它与多种皮肤反应有关，包括光敏性。我们描述了一名55岁男性的病例，该患者在开始使用凡德他尼一个月后，在阳光暴露部位出现了严重、疼痛、红斑性大疱性皮疹。该皮疹最初对类固醇治疗无效，严格避免日晒也未消退，但在口服（）提取物几周后最终消退。（）提取物源自一种热带蕨类植物，具有抗氧化作用，可通过炎症干扰和促进其他细胞毒性反应减轻紫外线引起的皮肤红斑。该病例说明了（）有潜力用作难治性光毒性反应的安全有效光保护剂。需要进一步的随机对照试验，以更好地了解（）在治疗酪氨酸激酶诱导的光毒性和其他皮肤病中的作用机制和光保护特性。
